Naturalistic Sleep Assessed by Wearable Devices in Parkinson Disease
NCT05348837
Recruiting
The cardinal motor features of Parkinson's disease (PD) include bradykinesia, rest tremor, and rigidity. Though non-motor features have been recognized for centuries, only recently has the prevalence and impact of non-motor symptoms become the focus of intense study. Disturbances of sleep are among the most common non-motor manifestations of PD; approximately two-thirds of PD patients experience sleep dysfunction of some kind. Given that sleep contributes to the regulation of many physiological... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/02/2025
Locations: University of Colorado Anschutz Medical Campus, Aurora, Colorado
Conditions: Parkinson Disease
Register for Updates
A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies
NCT05453903
Recruiting
The purpose of this study is to determine the recommended Phase 2 dose (RP2D) candidate(s) of bleximenib in combination with AML directed therapies (dose selection) and further to evaluate safety and tolerability of bleximenib in combination with AML directed therapies at the RP2D(s) (dose expansion).
Gender:
ALL
Ages:
12 years and above
Trial Updated:
04/02/2025
Locations: The University of Alabama at Birmingham, Birmingham, Alabama +31 locations
Conditions: Leukemia, Myeloid, Acute
Register for Updates
δ in Dementia Clinical Trials
NCT05592678
Recruiting
The goal of this clinical trial is to demonstrate potential improvements in clinical trial methods relating to dementia and cognitive decline. The main questions it aims to answer are: * Can an intervention's outcome be better assessed by a latent variable ("δ") integrating cognitive performance with functional status? * Can latent biomarkers of δ guide the selection of an intervention that will modulate dementia severity? * Can a latent variable, derived from information collected remotely fro... Read More
Gender:
ALL
Ages:
Between 65 years and 100 years
Trial Updated:
04/02/2025
Locations: Univeristy of Texas Health Science Center at San Antonio (UTHSCSA), San Antonio, Texas
Conditions: Alzheimer's Disease (AD), Dementia, Cognitive Decline, Mild Cognitivie Impairment (MCI)
Register for Updates
AFFINITY BEYOND: Anti-AAV8 Antibody Assessment Study of Boys With DMD
NCT05683379
Recruiting
This is an observational screening study to evaluate the prevalence of anti-adeno-associated serotype 8 (AAV8) antibodies in participants with Duchenne muscular dystrophy (DMD).
Gender:
MALE
Ages:
Between 0 years and 11 years
Trial Updated:
04/02/2025
Locations: Rare Disease Research, Atlanta, Georgia
Conditions: Duchenne Muscular Dystrophy
Register for Updates
Iltamiocel Compared to Placebo for Chronic Fecal Incontinence in Females With Obstetric Injury
NCT05776277
Recruiting
This study evaluates the efficacy and safety of a single injection of iltamiocel (300 x 10\^6 cells) compared to a placebo in the reduction of fecal incontinence episode frequency in adult female participants with chronic fecal incontinence and a history of obstetric anal sphincter injury. Half of the participants will receive iltamiocel (injections with cells) and the other half will receive placebo.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: UC San Diego Health, La Jolla, California +25 locations
Conditions: Fecal Incontinence
Register for Updates
Ovarian Tissue Cryopreservation for Fertility Preservation
NCT05875155
Recruiting
The goal of this observational study is to learn about fertility preservation for pre-pubertal, peri-pubertal, and adult participants that are unable to pursue clinical standard of care fertility preservation such as egg (oocyte) and embryo cryopreservation. In addition, this study will provide research tissue for the following Specific Aims: 1. To optimize techniques for cryopreservation of ovarian tissues from patients at significant risk for infertility. 2. To investigate factors affecting... Read More
Gender:
FEMALE
Ages:
39 years and below
Trial Updated:
04/02/2025
Locations: Magee-Womens Hospital, Pittsburgh, Pennsylvania
Conditions: Cancer, Autoimmune Diseases
Register for Updates
Comparative Pharmacokinetics and Pharmacodynamics of Synthetic Nicotine
NCT05962229
Recruiting
In a crossover study, experienced electronic cigarette users will vape 3 different forms of nicotine: natural (derived from tobacco), synthetic, or a 50:50 mixture of both natural and synthetic. The investigators will compare nicotine metabolism, cardiovascular effects, patterns of self-administration, and participants' feelings of craving/withdrawal and enjoyment.
Gender:
ALL
Ages:
Between 21 years and 65 years
Trial Updated:
04/02/2025
Locations: Zuckerberg San Francisco General Hospital (ZSFG), San Francisco, California
Conditions: Nicotine Dependence, Nicotine Vaping
Register for Updates
Preschool Hearing Screening
NCT06058767
Recruiting
Children who are deaf or hard-of-hearing (D/HH) are at risk of speech and language delays, which can be mitigated through early identification and intervention. Identifying hearing loss (HL) during preschool is crucial, but the most effective hearing screening method for preschoolers remains uncertain. The purpose of this study is to learn whether, compared to the gold-standard two-stage Pure-tone audiometry (PTA) + otoacoustic emissions (OAE) screening (TS-PO), single-stage OAE (SS-O) screening... Read More
Gender:
ALL
Ages:
Between 2 years and 6 years
Trial Updated:
04/02/2025
Locations: The University of California, San Francisco, San Francisco, California
Conditions: Hearing Loss, Hearing Disorders in Children, Hearing Loss, Sensorineural, Hearing Loss, Conductive, Hearing Loss, Unilateral, Hearing Loss, Noise-Induced, Hearing Loss, Mixed, Hearing Loss, Bilateral
Register for Updates
Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma
NCT06102005
Recruiting
This is a Phase 2b, global, multicenter, randomized, double-blind, placebo-controlled, parallel group, dose ranging study to assess the efficacy, safety, and tolerability of add-on therapy with SC lunsekimig in adult participants aged 18 to 80 years, (inclusive) with moderate-to-severe asthma.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/02/2025
Locations: Allergy, Asthma & Immunology Associates- Site Number : 8400009, Scottsdale, Arizona +155 locations
Conditions: Asthma
Register for Updates
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
NCT06150157
Recruiting
The purpose of this study is to characterize safety and to determine the Recommended Phase 2 Dose (RP2D\[s\]) and optimal dosing schedule(s) of JNJ-88549968, in part 1 (Dose Escalation); to characterize the safety of JNJ- 88549968 at RP2D(s), in part 2 (Cohort Expansion).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: City of Hope, Duarte, California +18 locations
Conditions: Myeloproliferative Disorders, Essential Thrombocythemia, Neoplasms, Myelofibrosis
Register for Updates
Brain Blood Flow Responses to Stress: Sex Differences
NCT06253702
Recruiting
Twenty-six otherwise healthy adults between 18-40 years of age composed of 13 males and 13 females will be enrolled in this study to determine how sex and sex hormones influence cerebral blood flow (CBF) control in healthy young adults without confounds of age or disease. Participants can expect to be on study for approximately 16 days.
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
04/02/2025
Locations: University of Wisconsin, Madison, Wisconsin
Conditions: Cerebrovascular Disorders
Register for Updates
Noncombustible Nicotine Delivery Systems as Potential Harm Reduction Tools for Persistent Cigarette Smokers
NCT06372899
Recruiting
This between-subjects study aims to evaluate whether e-cigarettes (ECIGS) versus oral nicotine pouches (ONPS) more readily substitute for combustible cigarettes among 200 cigarette smokers. After measuring baseline cigarette smoking rate, participants will be randomized to ECIGS or ONPS and be instructed to switch (versus smoking cigarettes) over a 6-week period. Relative reductions in biomarkers of exposure will be measured. ECIG- and ONP-associated subjective reward and the reinforcing value o... Read More
Gender:
ALL
Ages:
21 years and above
Trial Updated:
04/02/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: E-cigarette Use, Cigarette Smoking, Harm Reduction, Tobacco Use
Register for Updates